Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease | Zendy

Lawrence S. Honig | Zendy; Bruno Vellas | Zendy; Mark Woodward | Zendy; Merçé Boada | Zendy; Roger Bullock | Zendy; Michael Borrie | Zendy; Klaus Häger | Zendy; Niels Andreasen | Zendy; Elio Scarpini | Zendy; Hong LiuSeifert | Zendy; Michael Case | Zendy; Robert A. Dean | Zendy; Ann Marie Hake | Zendy; Karen Sundell | Zendy; Vicki Poole Hoffmann | Zendy; Christopher Carlson | Zendy; Rashna Khanna | Zendy; Mark A. Mintun | Zendy; Ronald B. DeMattos | Zendy; Katherine J. Selzler | Zendy; Eric Siemers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Author(s) -

Lawrence S. Honig,

Bruno Vellas,

Mark Woodward,

Merçé Boada,

Roger Bullock,

Michael Borrie,

Klaus Häger,

Niels Andreasen,

Elio Scarpini,

Hong LiuSeifert,

Michael Case,

Robert A. Dean,

Ann Marie Hake,

Karen Sundell,

Vicki Poole Hoffmann,

Christopher Carlson,

Rashna Khanna,

Mark A. Mintun,

Ronald B. DeMattos,

Katherine J. Selzler,

Eric Siemers

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1705971

Subject(s) - placebo , dementia , medicine , alzheimer's disease , mini–mental state examination , gastroenterology , psychology , pathology , disease , alternative medicine

Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research